Literature DB >> 17201412

Discovering potassium channel blockers from synthetic compound database by using structure-based virtual screening in conjunction with electrophysiological assay.

Hong Liu1, Zhao-Bing Gao, Zhiyi Yao, Suxin Zheng, Yang Li, Weiliang Zhu, Xiaojian Tan, Xiaomin Luo, Jianhua Shen, Kaixian Chen, Guo-Yuan Hu, Hualiang Jiang.   

Abstract

Potassium ion (K+) channels are attractive targets for drug discovery because of the essential roles played in biological systems. However, high-throughput screening (HTS) cannot be used to screen K+ channel blockers. To overcome this disadvantage of HTS, we have developed a virtual screening approach for discovering novel blockers of K+ channels. On the basis of a three-dimensional model of the eukaryotic K+ channels, molecular docking-based virtual screening was employed to search the chemical database MDL Available Chemicals Directory (ACD). Compounds were ranked according to their relative binding energy, favorable shape complementarity, and potential to form hydrogen bonds with the outer mouth of the K+ channel model. Twenty candidate compounds selected from the virtual screening were examined using the whole-cell voltage-clamp recording in rat dissociated hippocampal neurons. Among them, six compounds (5, 6, 8, 18-20) potently blocked both the delayed rectifier (IK) and fast transient K+ currents (IA). When applied externally, these six compounds preferentially blocked IK with potencies 2- to 500-fold higher than that of tetraethylammonium chloride. Intracellular application of the six compounds had no effect on both K+ currents. In addition, the interaction models and binding free energy calculations demonstrated that hydrophobic interaction and solvent effects play important roles in the inhibitory activities of these compounds. The results demonstrated that structure-based computer screening strategy could be used to identify novel, structurally diverse compounds targeting the pore binding pocket of the outer mouth of voltage-gated K+ channels. This study provides an alternative way of finding new blockers of voltage-gated K+ channels, while the techniques for high-throughput screening of K+ channel drugs remain in development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17201412     DOI: 10.1021/jm060414o

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

Review 1.  Carbohydrate recognition by boronolectins, small molecules, and lectins.

Authors:  Shan Jin; Yunfeng Cheng; Suazette Reid; Minyong Li; Binghe Wang
Journal:  Med Res Rev       Date:  2010-03       Impact factor: 12.944

2.  A practical and efficient route for the highly enantioselective synthesis of mexiletine analogues and novel beta-thiophenoxy and pyridyl ethers.

Authors:  Kun Huang; Margarita Ortiz-Marciales; Viatcheslav Stepanenko; Melvin De Jesús; Wildeliz Correa
Journal:  J Org Chem       Date:  2008-08-09       Impact factor: 4.354

3.  GATED PORES IN THE FERRITIN PROTEIN NANOCAGE.

Authors:  Elizabeth C Theil; Xiaofeng S Liu; Takehiko Tosha
Journal:  Inorganica Chim Acta       Date:  2008-03-03       Impact factor: 2.545

4.  Specific and slow inhibition of the kir2.1 K+ channel by gambogic acid.

Authors:  Elena Zaks-Makhina; Hui Li; Anatoly Grishin; Vicenta Salvador-Recatala; Edwin S Levitan
Journal:  J Biol Chem       Date:  2009-04-13       Impact factor: 5.157

5.  Spiroborate ester-mediated asymmetric synthesis of beta-hydroxy ethers and its conversion to highly enantiopure beta-amino ethers.

Authors:  Kun Huang; Margarita Ortiz-Marciales; Wildeliz Correa; Edgardo Pomales; Xaira Y López
Journal:  J Org Chem       Date:  2009-06-05       Impact factor: 4.354

6.  Identification of selective inhibitors of the potassium channel Kv1.1-1.2((3)) by high-throughput virtual screening and automated patch clamp.

Authors:  Sören J Wacker; Wiktor Jurkowski; Katie J Simmons; Colin W G Fishwick; A Peter Johnson; David Madge; Erik Lindahl; Jean-Francois Rolland; Bert L de Groot
Journal:  ChemMedChem       Date:  2012-03-30       Impact factor: 3.466

7.  Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase.

Authors:  Xiaoyu Zeng; Lin Liu; Mengzhu Zheng; Huimin Sun; Juanjuan Xiao; Tao Lu; Guangqian Huang; Pianpian Chen; Jianmin Zhang; Feng Zhu; Hua Li; Qiuhong Duan
Journal:  Oncotarget       Date:  2016-04-19

8.  Ionic channels as targets for drug design: a review on computational methods.

Authors:  Gregorio Fernández-Ballester; Asia Fernández-Carvajal; José Manuel González-Ros; Antonio Ferrer-Montiel
Journal:  Pharmaceutics       Date:  2011-12-09       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.